Bone anchored hearing aid (Baha) implant is an option for patient with canal atresia, single sided deafness(SSD) and chronically discharging ears despite treatments. This retrospective study was conducted from 2001 to 2011 to evaluate the surgical outcome of Baha implant surgery. Thirty-three patients were identified during this study period. Their age at implantation ranged from 5 to 40 years. Of 33 patients, 29 (87.9 %) patients had bilateral microtia and canal atresia, 3 (9.1 %) patients had unilateral microtia and canal atresia and 1 (3.0 %) patients have SSD following labyrinthitis. One patient (3.2 %) had major complication which is lost of implant due to failure of osseointegration. Soft tissue reactions were seen 7 patients (21.1 %). Of these 7 patients, 4 patients required 3-4 procedures as day care operation for excision of the skin overgrowth surrounding the abutment. Recurrent antibiotic treatment was required in 3 patients (9.7 %). None of our patient had history of intraoperative or peri-operative complication following Baha surgery. The commonest complications are local infection and inflammation at the implant site. None of our patient had history of intraoperative or peri-operative complication following Baha implant surgery.

UAF should be highly suspected in patients with long-term ureteral stents, especially if gross hematuria develops. The placement of a metallic ureteral stent using a high-pressure balloon should be performed cautiously, especially in patients with a history of pelvic surgery or radiation.

Purpose To evaluate the impact of preoperative renal impairment on the oncological outcomes of patients with urothelial carcinoma who underwent radical cystectomy. Materials and Methods We retrospectively reviewed the medical records of patients with urothelial carcinoma who underwent radical cystectomy from 2004 to 2017. All patients who underwent preoperative 99m Tc-diethylenetriaminepentaacetic acid renal scintigraphy (DTPA) were identified. We divided the patients into two groups according to their glomerular filtration rates (GFRs): GFR group 1, GFR≥90 mL/min/1.73 m 2 ; GFR group 2, 60≤GFR<90 mL/min/1.73 m 2 . We included 89 patients in GFR group 1 and 246 patients in GFR group 2 and compared the clinicopathological characteristics and oncological outcomes between the two groups. Results The mean time required for recurrence was 125.5±8.0 months in GFR group 1 and 85.7±7.4 months in GFR group 2 (p=0.030). The mean cancer-specific survival was 131.7±7.8 months in GFR group 1 and 95.5±6.9 months in GFR group 2 (p=0.051). The mean overall survival was 123.3±8.1 months in GFR group 1 and 79.5±6.6 months in GFR group 2 (p=0.004). Conclusions Preoperative GFR values in the range of 60≤GFR<90 mL/min/1.73 m 2 are independent prognostic factors for poor recurrence-free survival, cancer-specific survival, and overall survival in patients after radical cystectomy compared with GFR values of ≥90 mL/min/1.73 m 2 .

In the T-group, IIEF-EF (maximum score: 30) increased by 8.4AE0.4 [95% CI: 7.7;9.1] at 10 years (p<0.0001). The improvement was statistically significant vs. previous year for 9 years and significant vs baseline throughout the observation time. In CTRL, IIEF-EF declined by 12.8AE0.3 [95% CI: -13.5;-12.1] at 10 years (p<0.0001) with statistical significance vs. previous year for 10 years. The estimated adjusted difference between groups at 10 years: 21.2 [95% CI: 20;22.4] (p<0.0001).Diabetes and weight control: In the T-group, HbA 1c dropped by 2.9AE0.1% [95% CI: -3.2;-2.7] (p<0.0001) while in CTRL patients it increased by 3.2AE0.1% [95% CI: 3;3.5] (p<0.0001) with statistical significance vs. previous year for 7 years (T-group) and 10 years (CTRL), respectively.In the T-group, men lost 19AE0.4% weight [95% CI: -19.8;-18.2] (p<0.0001) while CTRL patients gained 4.8AE0.4% [95% CI: 4.1;5.6] (p<0.0001) with statistical significance vs. previous year for 9 years (Tgroup) and 10 years (CTRL), respectively.Adherence to testosterone was 100% as all injections were administered in the office and documented. No patient dropped out.CONCLUSIONS: In hypogonadal men with T2DM, TTh improves and preserves urinary and erectile function for a prolonged period of time. Long-term testosterone therapy results in improved glycemic control and weight loss.Source of Funding: Bayer provided partial funding for data entry and statistical analyses.